Stifel Nicolaus Upgrades Masimo (NASDAQ:MASI) to Buy

Masimo (NASDAQ:MASI) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research note issued on Monday, Marketbeat reports. The firm currently has a $170.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $148.00. Stifel Nicolaus’ target price points to a potential upside of 23.03% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the stock. Wells Fargo & Company upgraded shares of Masimo from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $117.00 to $160.00 in a research note on Monday, March 25th. Piper Sandler raised their price target on shares of Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a research note on Monday, February 26th. Jefferies Financial Group restated a “hold” rating and set a $121.00 price target (up previously from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. Needham & Company LLC cut shares of Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, BTIG Research raised their price target on shares of Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday, March 25th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Masimo currently has a consensus rating of “Hold” and a consensus price target of $137.43.

Masimo Trading Up 0.1 %

Shares of NASDAQ:MASI opened at $138.18 on Monday. The company has a market cap of $7.31 billion, a P/E ratio of 91.39 and a beta of 0.97. The stock’s 50-day moving average is $135.58 and its 200-day moving average is $113.53. Masimo has a 52-week low of $75.22 and a 52-week high of $198.00. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The business had revenue of $548.90 million during the quarter, compared to analysts’ expectations of $545.69 million. During the same quarter last year, the company earned $1.32 earnings per share. The firm’s revenue was down 11.0% on a year-over-year basis. Equities research analysts predict that Masimo will post 3.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MASI. Riverview Trust Co bought a new position in shares of Masimo in the first quarter valued at approximately $25,000. Massmutual Trust Co. FSB ADV increased its holdings in shares of Masimo by 140.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares in the last quarter. Byrne Asset Management LLC acquired a new stake in shares of Masimo in the fourth quarter valued at approximately $28,000. DHJJ Financial Advisors Ltd. acquired a new stake in shares of Masimo in the third quarter valued at approximately $32,000. Finally, NBC Securities Inc. acquired a new stake in shares of Masimo in the third quarter valued at approximately $34,000. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.